⌖ 22 Orbeli Bros. str., 0028 Yerevan, Armenia☎ +374 10 272247✉ info@physiol.sci.am

Antibody-based Immunotherapeutics Research Group

(In the Lab of Toxinology)
Gayane Kirakosyan

Gayane Kirakosyan

Head of Scientific Group

PhD

E-mail: gkirakosyan@ysu.am

Overvew

Established in 2026, the Antibody-Based Immunotherapeutics Research Group develops passive immunotherapy platforms based on polyclonal and hyperimmune immunoglobulins for clinically important bacterial and viral infections. The group combines experimental immunization models, plasma and serum fractionation, IgG purification, antibody characterization, quality assessment, and in vitro and in vivo evaluation. Its current flagship project focuses on the development of hyperimmune IgG against multidrug-resistant Staphylococcus aureus (MRSA). The long-term vision is to establish locally adaptable, quality-controlled technologies for specialized immunoglobulin preparations relevant to Armenia and comparable small or resource-limited settings.

Main Aim

To develop safe, reproducible, and quality-controlled antibody-based preparations for passive immunotherapy against infectious agents, bacterial toxins, viral targets, and other immunologically relevant antigens.

Scientific Directions

·        Antibody-based passive immunotherapy for bacterial and viral infections.

·        Polyclonal and hyperimmune IgG technologies.

·        Mini-pool plasma and serum fractionation for IgG purification from human and animal plasma/serum sources.

·        Antimicrobial and resistance-modulating strategies, with a current focus on MRSA.

·        Quality control and biological safety assessment of protein and immunoglobulin preparations.

·        Natural bioactive factors with antimicrobial, cytotoxic, and toxicological relevance.

Objectives

·        Establish reproducible immunization schemes and hyperimmune serum/plasma collection procedures.

·        Optimize mini-pool fractionation and purification workflows for human and animal plasma/serum-derived IgG.

·        Generate and characterize high-titer polyclonal IgG against selected infectious and toxin-associated targets.

·        Define analytical quality criteria for immunoglobulin fractions, including concentration, purity, composition, stability, sterility, endotoxin content, pyrogenicity, and biological safety.

·        Evaluate functional activity using antibody-binding and neutralization assays, antimicrobial and resistance-modulation tests, and in vitro and in vivo infection models.

·        Advance candidate immunoglobulin preparations for translational research and collaborative development.

Methods and Experimental Platforms

·        Experimental animal immunization and collection of hyperimmune serum/plasma.

·        Human and animal serum/plasma processing using cold ethanol fractionation, clarification/depth filtration, tangential-flow ultrafiltration/diafiltration, and viral-removal approaches, including nanofiltration.

·        Protein and IgG characterization using protein quantification, immunoelectrophoresis, horizontal agarose gel electrophoresis where applicable, and chromatographic analysis.

·        Assessment of antibody binding, neutralizing activity, and biological functionality.

·        Antimicrobial assays, including MIC/MBC determination, checkerboard microdilution synergy assays, anti-biofilm assays, and time-kill kinetics.

·        Safety and biocompatibility assessment, including sterility, endotoxin content, pyrogenicity, cell viability, and biological safety testing.

·        In vivo evaluation of developed immunoglobulin preparations in experimental infection models.

Facilities and Technical Infrastructure

The group uses infrastructure required for the separation, purification, characterization, and quality assessment of protein and immunoglobulin preparations. Available capabilities include freezing, centrifugation, clarification and depth filtration, electrophoretic analysis, spectrophotometric measurements, microbiological studies, cell-based assays, and experimental animal models. These facilities support the research pipeline from antigen selection and immunization to IgG purification, quality control, and preclinical evaluation.

Publications

1. Ginovyan M., Kirakosyan G. Adapting the Cohn 6th cold ethanol fractionation method for small plasma pools: An innovative platform for developing hyperimmunoglobulin products against antibiotic-resistant infections in resource-limited settings. Transfusion and Apheresis Science, 2025, 64(2), 104093. DOI: 10.1016/j.transci.2025.104093.

2. Ginovyan M., Daghbashyan S., Kirakosyan G. Development of plasma fractionation infrastructure in low- and middle-income countries — success story of Armenia in meeting domestic demand for anti-D immunoglobulin. Poster and oral session presented at the 38th ISBT International Congress, Barcelona, Spain, 2024. Vox Sanguinis, 2024, 119(Suppl. 1), pp. 276–277. DOI: 10.1111/vox.13652; 10.13140/RG.2.2.10137.22884.

3. Ginovyan M., Kirakosyan G. Optimizing Cohn 6th cold ethanol fractionation method for small plasma pools: A platform for hyperimmunoglobulin development against multidrug-resistant staphylococcal infections in resource-limited settings. Poster presentation at FEBS European Workshop on Bacterial Protein Toxins, ETOX 2025, Oñati, Spain, Abstract Book, p. 22.

4 Ginovyan M., Kirakosyan G., Musayelyan N., Hovhannisyan S., Shamilyan A. Establishing a sustainable anti-D hyperimmune plasma donation program in a small resource-limited setting: The Armenian experience. 39th International ISBT Congress, Kuala Lumpur, Malaysia, 2026, 121(S1):94–95. Vox Sanguinis, Abstract PA21-L03. DOI: 10.1111/vox.70275.

5. Kirakosyan G., Matevosyan L., Antonyan I., Mkrtchyan A., Ayvazyan N., Ginovyan M. Potent bactericidal activity of Macrovipera lebetina obtusa venom against multidrug-resistant Staphylococcus aureus. Abstract Book of COST Action CA21145 EURESTOP Final Conference, Pula, Croatia, 2026, p. 40.